Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
33 hedge funds and large institutions have $353M invested in Cyteir Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$90.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$60.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$35.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$33.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.9M |
Top Sellers
CYT Hedge Fund Activity: Q2 2021 in Review
33 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q2 2021, worth a combined $353M.
Buyers outnumbered sellers: 33 funds opened new CYT positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $90.7M.
- 33 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $353M of Cyteir Therapeutics, Inc. Common Stock stock for Q2 2021.
- 33 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +33 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q2 2021 was Novo Holdings A/S, an estimated $90.7M added.
Based on aggregated 13F filings for Q2 2021.